Why Ensign Group is on investors’ radar today
Ensign Group (ENSG) has drawn attention after recent share price moves, with the stock showing mixed short term performance alongside stronger gains over the past 3 months and year.
See our latest analysis for Ensign Group.
At the current share price of $209.46, Ensign Group’s recent 1 day and 1 month share price returns have softened slightly. However, the 90 day share price return of 19.45% and 1 year total shareholder return of 61.61% suggest momentum has been building over a longer period.
If you are comparing Ensign Group with other opportunities in healthcare, this is a good moment to scan for companies riding similar trends through the 33 healthcare AI stocks
With Ensign Group trading at $209.46, sitting close to an average analyst price target of $220.40 but at an estimated 40.68% premium to intrinsic value, are you looking at a genuine opportunity or a market that is already pricing in future growth?
Preferred P/E of 35.1x: Is it justified?
At a last close of $209.46, Ensign Group is trading on a P/E of 35.1x, which places the stock at a clear premium compared with both its peer group and the wider US Healthcare industry.
The P/E ratio compares the current share price with earnings per share, so a higher multiple usually reflects the market paying more today for each dollar of current earnings. For a business like Ensign Group, which provides skilled nursing, senior living and related services, that kind of premium often signals that investors are comfortable paying up for its earnings profile and business model.
Against that backdrop, the numbers indicate a stretched valuation. The current P/E of 35.1x is well above the estimated fair P/E of 29.1x, a level the market could move towards if expectations cool. It also sits far ahead of the US Healthcare industry average of 22.1x and the peer average of 17x, meaning investors today are accepting a valuation that is materially richer than both sector norms and closer peers.
Explore the SWS fair ratio for Ensign Group
Result: Price-to-earnings of 35.1x (OVERVALUED)
However, stretched valuation and any slowdown in revenue or net income growth, currently at 10.19% and 13.22%, could quickly challenge the premium investors are paying.
Find out about the key risks to this Ensign Group narrative.
DCF check, is the premium really that high?
While the P/E points to a rich price, our DCF model also suggests Ensign Group is not cheap. With the share price at $209.46 versus an estimated future cash flow value of $148.89, the stock screens as overvalued on cash flows too. What might convince you this gap is acceptable?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ensign Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With sentiment this mixed, it makes sense to move quickly, review the facts, and decide where you stand based on the 2 key rewards.
Looking for more investment ideas?
If Ensign Group has your attention, do not stop here. Broaden your watchlist with other focused ideas that could support your portfolio decisions using targeted stock screens.
- Target potential value opportunities by scanning a curated set of 47 high quality undervalued stocks that combine quality fundamentals with compressed pricing.
- Strengthen your income focus by reviewing 15 dividend fortresses that aim to pair robust yields with resilient business profiles.
- Prioritise resilience by checking 74 resilient stocks with low risk scores that score well on financial stability and downside protection.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com